Income Statement

v3.20.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)    
Revenues, net $ 36,895 $ 65,274
Operating expenses:    
Cost of implants and other costs 22,934 2,820
Research and development 710,510 145,965
Selling, general and administrative 801,946 1,394,665
Depreciation and amortization 19,171 2,194
Total operating expenses 1,554,561 1,545,644
Loss from operations (1,517,666) (1,480,370)
Other income (expenses):    
Interest expense, net (125,407) (514,168)
Grant income 564,086 224,059
Other miscellaneous income 799
Total other income (expenses) 439,478 (290,109)
Net loss before provision for income taxes (1,078,188) (1,770,479)
Income taxes
Net loss (1,078,188) (1,770,479)
Non-controlling interest 11,626 28
NET LOSS ATTRIBUTIBLE TO BIOCORRX, INC. $ (1,066,562) $ (1,770,451)
Net loss per common share, basic and diluted $ (0.20) $ (0.67)
Weighted average number of common shares outstanding, basic and diluted 5,335,054 2,627,864

Source